Senda Ajroud-Driss

Medicine & Life Sciences

1. Amyotrophic Lateral Sclerosis 100%
2. Chronic Inflammatory Demyelinating Polyradiculoneuropathy 54%
3. Amyotrophic lateral sclerosis 1 47%
4. Hizentra 41%
5. patisiran 38%
6. Polyneuropathies 33%
7. Peripheral Nervous System Diseases 30%
8. Diabetes Complications 30%
9. Amyloidosis, Hereditary, Transthyretin-Related 29%
10. Type 1 Diabetes Mellitus 28%
11. Diabetic Neuropathies 24%
12. Safety 23%
13. RNAi Therapeutics 21%
14. Intravenous Immunoglobulins 21%
15. Placebos 21%
16. Epidemiology 19%
17. Spinal Muscular Atrophy 16%
18. Mutation 16%
19. Superoxide Dismutase-1 16%
20. Therapeutics 13%
21. Motor Neurons 13%
22. Genes 13%
23. Cerebrospinal Fluid 11%
24. nusinersen 11%
25. Plasmids 11%
26. Schizophrenia 10%
27. Antipsychotic Agents 10%
28. Riluzole 10%
29. Hepatocyte Growth Factor 10%
30. human HGF protein 10%
31. Quality of Life 9%
32. Small Fiber Neuropathy 9%
33. Hand Strength 9%
34. Simendan 9%
35. Limb-Girdle Muscular Dystrophies 9%
36. Mitochondrial Myopathies 9%
37. DNA 9%
38. Pyrimethamine 9%
39. Wolff-Parkinson-White Syndrome 8%
40. Charcot-Marie-Tooth Disease 8%
41. Myotonic Dystrophy 8%
42. Molecular Models 8%
43. Spinal Injections 8%
44. Noninvasive Ventilation 8%
45. Cytochrome P-450 CYP1A1 8%
46. Rabies 8%
47. Placebo Effect 7%
48. Lyme Disease 7%
49. Chickenpox 7%
50. Gastrostomy 7%